Dr. Dhiraj, Ph.D.

Employment

• National Institutes of Health Visiting Fellow
  2022 - Present
• Jamia Millia Islamia CSIR Research Fellow
  2021 - 2022

Education

• Delhi Technological University Doctorate of Philosophy in Biotechnology
  2014 - 2019
• Delhi Technological University Master of Technology in Bioinformatics
  2012 - 2014
• Netaji Subhas Institute of Technology Bachelor of Engineering in Biotechnology
  2008 - 2012

Projects & Funding

Projects & funding information is unavailable.

Publications (29)

• Molecular dynamics of cognitive-motor impairment in neurodegenerative diseases
  Frontiers in Molecular Neuroscience 2023 DOI: 10.3389/FNMOL.2023.1237769
  +Save
• Regulation of receptor tyrosine kinase gene expression
  2023 DOI: 10.1016/B978-0-443-18677-6.00004-X
  +Save
• Therapeutic targeting of Huntington's disease: Molecular and clinical approaches
  Biochemical and Biophysical Research Communications 2023 DOI: 10.1016/j.bbrc.2023.02.075
  +Save
• Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation
  Drug Discovery Today 2022 DOI: 10.1016/J.DRUDIS.2022.06.005
  +Save
• Recent advances in the therapeutic development of ERK inhibitors
  Protein Kinase Inhibitors 2022 DOI: 10.1016/B978-0-323-91287-7.00023-5
  +Save
• Targeted protein degraders march towards the clinic for neurodegenerative diseases
  Ageing Research Reviews 2022 DOI: 10.1016/J.ARR.2022.101616
  +Save
• Therapeutic Integrity of Microbiome-based Medicines in Neurodegenerative Disorders
  Current Neuropharmacology 2022 DOI: 10.2174/1570159X20666220214113816
  +Save
• Neurodegenerative brain models vs. cell replacement or restoration therapy: A review on promises and pitfalls
  Biochemical and Biophysical Research Communications 2021 DOI: 10.1016/j.bbrc.2021.11.040
  +Save
• Ultra-sensitive techniques for detecting neurological biomarkers: Prospects for early diagnosis
  Biochemical and Biophysical Research Communications 2021 DOI: 10.1016/j.bbrc.2021.10.073
  +Save
• Topical Insights Into the Post-Approval Controversies of Aducanumab
  Frontiers in Pharmacology 2021 DOI: 10.3389/fphar.2021.787303
  +Save